Roles
- Associate Professor of Clinical Medicine
-
Biography
Dr. Frances Valdes received her medical degree from Johns Hopkins University School of Medicine, completed her residency at the University of California, San Francisco, and her fellowship at City of Hope–Harbor–UCLA. She has a clinical interest in breast cancer, colorectal cancer, esophageal and stomach cancer, gynecological cancer, and neck cancer. She is board certified in both medical oncology and internal medicine. -
Education & Training
Education
-
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 28 clinical trials.
-
A Phase 1b Dose Escalation and Expansion Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 as Monotherapy and in Combination With Other Anticancer Agents in Adults With Advanced Solid Malignancies
- Principal Investigator: Frances Valdes
- Study Phase: Phase 1
- Enrollment Status: Closed
-
A Phase 1 Open-label, Multicenter Dose Escalation and Expansion Study of MT-5111 in Subjects With Previously Treated Advanced HER2-positive Solid Tumors
- Principal Investigator: Frances Valdes
- Study Phase: Phase 1
- Enrollment Status: Closed
-
A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With gBRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
- Principal Investigator: Frances Valdes
- Study Phase: Phase 3
- Enrollment Status: Not Accepting
-
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
- Principal Investigator: Frances Valdes
- Study Phase: Phase 3
- Enrollment Status: Closed
-
A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
- Principal Investigator: Frances Valdes
- Study Phase: Phase 3
- Enrollment Status: Closed
-
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
- Principal Investigator: Frances Valdes
- Study Phase: Phase 3
- Enrollment Status: Not Accepting
-
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
- Principal Investigator: Frances Valdes
- Study Phase: Phase 3
- Enrollment Status: Closed
-
A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
- Principal Investigator: Frances Valdes
- Study Phase: Phase 2
- Enrollment Status: Closed
-
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
- Principal Investigator: Frances Valdes
- Study Phase: Phase 3
- Enrollment Status: Closed
-
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
- Principal Investigator: Frances Valdes
- Study Phase: Phase 3
- Enrollment Status: Not Accepting
-
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
- Principal Investigator: Frances Valdes
- Study Phase: Phase 3
- Enrollment Status: Not Accepting
-
To evaluate whether 6 months of combined neoadjuvant (neo)/adjuvant HER2 blockade results in a non-inferior recurrence-free survival (RFS) compared to 12 months of combined neo/adjuvant HER2 blockade, in patients with early stage HER2+ breast cancer who achieve pCR after neoadjuvant chemotherapy with HER2 blockade.
- Principal Investigator: Frances Valdes
- Study Phase: Phase III
- Enrollment Status: Open
-
The primary objective is to assess in Step 2 of the study whether an early switch of ET coupled with CDK4/6i (Arm 2) will improve treatment efficacy compared to non-switch treatment (Arm 1) in the first 160 patients from Step 1 who have a rise in ctDNA ratio>1 prior to clinical progression. The primary endpoint is progression-free-survival (PFS) in Arms 1 and 2, which will be called PFS1, and is defined as the elapsed time from the date of randomization (at time a rise in ctDNA ratio>1 is detected prior to clinical progression) to the date of clinical progression or death in randomized patients.
- Principal Investigator: Frances Valdes
- Study Phase: Phase II
- Enrollment Status: Not Accepting
-
There are two main purposes of this study; the first is to evaluate whether the study drug is safe and can be tolerated, and to identify the highest dose that can safely be given. The second main purpose is to find out whether the study drug is effective at reducing the study participants tumors.
- Principal Investigator: Frances Valdes
- Study Phase: Phase I
- Enrollment Status: Open
-
This study is a combined trial that will include the investigation of a medicinal product (DB-1303) and an evaluation of an in vitro diagnostic test that measure human epidermal growth factor receptor 2 (HER2) protein expression in human samples. The in vitro diagnostic test will be used to identify people who have HER2 protein expression levels and could benefit from treatment with DB-1303. The aim of this combined trial is to evaluate the safety and efficacy of the DB-1303 medicinal product and establish or confirm the clinical performance of an in vitro diagnostic test.
- Principal Investigator: Frances Valdes
- Study Phase: Phase III
- Enrollment Status: Closed
-
A Phase 1/2, Open Label, Dose-Escalation and Expansion Study of Oral ORIN1001 With and Without Chemotherapy in the Treatment of Subjects With Solid Tumors
- Principal Investigator: Frances Valdes
- Study Phase: Phase 1/Phase 2
- Enrollment Status: Closed
-
The purpose of this study is to compare two commonly used treatment choices for early-stage breast cancer in premenopausal women.
- Principal Investigator: Frances Valdes
- Study Phase: Phase III
- Enrollment Status: Open
-
- To evaluate the safety and tolerability of BAL0891 in adult patients with advanced solid tumors administered as monotherapy and in combination with carboplatin or paclitaxel or tislelizumab- To estimate the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of BAL0891 monotherapy and BAL0891-carboplatin/paclitaxel combination treatments
- Principal Investigator: Frances Valdes
- Study Phase: Phase I
- Enrollment Status: Open
-
A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With Metastatic Breast Cancer (mBCA) Who Have Progressed Through Prior Hormonal Therapy
- Principal Investigator: Frances Valdes
- Study Phase: Phase 2
- Enrollment Status: Closed
-
The main goal of this study is to test whether the study drug is safe and tolerable in patients with advanced/metastatic solid tumors (including non-small cell lung cancer [NSCLC], breast cancer [BC], prostate cancer, head and neck squamous cell carcinoma [HNSCC], Esophageal Squamous Cell Carcinoma [ESCC] and Biliary Tract Cancer [BTC]). This study will also measure the amount of the study drug in your blood at different time points, determine whether antibodies (proteins in your blood) against the study drug are produced in your body, and assess the effect of the study drug on your disease. In addition, this study may also explore the relationship between biomarkers (a biological molecule found in blood or tissue that may be a sign of a disease) in your body and the effect of the study drug on your disease.
- Principal Investigator: Frances Valdes
- Study Phase: Phase I/II
- Enrollment Status: Closed
-
The purpose of this clinical trial is to see how well IMP1734 works alone and in combination with other cancer fighting drugs. Specifically, this study will test how well IMP1734 is tolerated alone and in combination with cancer fighting drugs in treating patients with ovarian, breast, prostate, and pancreatic cancer.
- Principal Investigator: Frances Valdes
- Study Phase: Phase I
- Enrollment Status: Open
-
A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355)
- Principal Investigator: Frances Valdes
- Study Phase: Phase 3
- Enrollment Status: Closed
-
To evaluate whether the recurrence-free interval (RFI) with low-dose tamoxifen is non-inferior to standard-of-care endocrine therapy among post-menopausal women with early-stage, low molecular risk breast cancer.
- Principal Investigator: Frances Valdes
- Study Phase: Phase III
- Enrollment Status: Not Accepting
-
The purpose of this study is to learn about the effects of disitamab vedotin for treating advanced breast cancer. This study will look at how disitamab vedotin works on you and test the safety and impact of disitamab vedotin on your body.
- Principal Investigator: Frances Valdes
- Study Phase: Phase II
- Enrollment Status: Not Accepting
-
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
- Principal Investigator: Frances Valdes
- Study Phase: Phase 2
- Enrollment Status: Closed
-
In this study, the experimental drug called GDC-4198 will be given to patients alone or in combination with another experimental drug, giredestrant, or patients will receive abemaciclib, a CDK4/6 inhibitor approved by regulatory authorities, in combination with giredestrant.
- Principal Investigator: Frances Valdes
- Study Phase: Phase I/II
- Enrollment Status: Open
-
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)
- Principal Investigator: Frances Valdes
- Study Phase: Phase 3
- Enrollment Status: Closed
-
To evaluate whether 6 months of combined neoadjuvant (neo)/adjuvant HER2 blockade results in a non-inferior recurrence-free survival (RFS) compared to 12 months of combined neo/adjuvant HER2 blockade, in patients with early stage HER2+ breast cancer who achieve pCR after neoadjuvant chemotherapy with HER2 blockade.
- Principal Investigator: Frances Valdes
- Study Phase: Phase III
- Enrollment Status: Open
